WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Vistagen Therapeutics revenue was $486.00k for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was -$15.0k, down 106.4% from last quarter. For the last reported fiscal year 2025 ending Mar 31, 2025, VTGN annual revenue was $486.0k, with -54.3% growth year-over-year.

VTGN past revenue growth

How has VTGN's revenue growth performed historically?

Company
-54.32%
Industry
150.53%
Market
20.47%
VTGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VTGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

VTGN revenue history

Current Revenue
$486.0k
Current Earnings
-$51.4M
Current Profit Margin
-10,579.8%

Be the first to know when VTGN announces revenue.

VTGN Revenue History By Year

VTGN Yearly RevenueVTGN RevenueVTGN ChangeVTGN Revenue Growth
2025-03-31$486.00k-$578.00k-54.32%
2024-03-31$1.06M$1.29M-568.72%
2023-03-31-$227.00k-$1.34M-120.47%
2022-03-31$1.11M$19.40k+1.78%
2021-03-31$1.09MN/AN/A
2020-03-31$0.00N/AN/A
2019-03-31$0.00N/AN/A
2018-03-31$0.00-$1.25M-100.00%
2017-03-31$1.25MN/AN/A
2016-03-31$0.00N/AN/A
2015-03-31$0.00N/AN/A
2014-03-31$0.00-$200.40k-100.00%
2013-03-31$200.40k-$1.14M-85.07%
2012-03-31$1.34M-$728.80k-35.19%
2011-03-31$2.07MN/AN/A

1 of 1

Vistagen Therapeutics Revenue FAQ

What was VTGN's revenue last quarter?

Vistagen Therapeutics (NASDAQ: VTGN) reported Q1 2025 revenue of -$15.00 thousand up 107.61% year over year. In the same quarter last year, Vistagen Therapeutics's revenue was $197.00 thousand.

What was Vistagen Therapeutics's revenue in 2025?

Vistagen Therapeutics's annual revenue for the twelve months ending Mar 31, 2025 was $486.00 thousand, a 54.32% decrease year over year.

How much does Vistagen Therapeutics make in a day?

Based on Vistagen Therapeutics annual revenue for the past five years, VTGN makes an average of $1,929.53 per day.

What was Vistagen Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Vistagen Therapeutics's revenue has grown -54.32% year over year. This is 204.85 percentage points lower than the US Biotechnology industry revenue growth rate of 150.53%. Vistagen Therapeutics's revenue in the past year totaled $486.00 thousand.

How much does Vistagen Therapeutics make in a year?

Vistagen Therapeutics's revenue by year for the past five years is:
  • Vistagen Therapeutics's revenue for the twelve months ending Mar 31, 2025 was $486.00 thousand, a 54.32% decrease year over year.
  • Vistagen Therapeutics's annual revenue for Mar 31, 2024 was $1.06 million, a 568.72% decrease from 2023.
  • Vistagen Therapeutics's annual revenue for 2023 was -$227.00 thousand, a 120.47% decrease from 2022.
  • Vistagen Therapeutics's annual revenue for 2022 was $1.11 million, a 1.78% increase from 2021.
  • Vistagen Therapeutics's annual revenue for 2021 was $1.09 million, a Infinity% increase from 2020.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.